Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs

Current Opinion in Lipidology

Volumn 18, Issue 6, 2007, Pages 613-621

  Duivenvoorden, Raphael ^a   Nederveen, Aart J ^a   De Groot, Eric ^a   Kastelein, John J P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; Clinical endpoint; Imaging; Surrogate endpoint

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; COLESTIPOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; TORCETRAPIB;

ARTERY WALL; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFICACY; HUMAN; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OSTEOPOROSIS; POPULATION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME; ULTRASOUND;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BIOMARKERS, PHARMACOLOGICAL; CARDIOVASCULAR AGENTS; DIAGNOSTIC IMAGING; DRUG DESIGN; HUMANS;

EID: 36048959491     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f19608     Document Type: Review

References (76)

1. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-440.
2. Boissel J-P, Collet J-P, Moleur P, et al. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43:235-244.
3. Sankatsing RR, de Groot E, Jukema JW. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005; 16:434-441.
4. Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74:1399-1406.
5. Poli A, Tremoli E, Colombo A, et al. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients: a new model for the quantification and follow up of preclinical atherosclerosis. Atherosclerosis 1988; 70:253-261.
6. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994; 14:177-192.
7. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146:483-494.
8. O'Leary DH, Polak JF, Kronmal RA, et al. The Cardiovascular Health Study Collaborative Research Group: carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340:14-22.
9. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96:1432-1437.
10. Hollander M, Bots ML, del Sol AI, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: The Rotterdam Study. Circulation 2002; 105:2872-2877.
11. Rosvall M, Janzon L, Berglund G. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005; 257:430-437.
12. Rosvall M, Janzon L, Berglund G. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 2005; 179:325-331.
13. Lorenz MW, von Kegler S, Steinmetz H, et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006; 37:87-92. Epidemiological study showing that carotid IMT independently predicts future vascular events and that its predictive value is at least as high in younger subjects as in older subjects.
14. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115:459-467. A meta-analysis of data from eight epidemiological studies showing that carotid IMT is a strong predictor of future vascular events.
15. Wittekoek ME, de Groot E, Prins MH, et al. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146:271-279.
16. Kastelein JJP, de Groot E, Sankatsing RR. Atherosclerosis measured by B-Mode ultrasonography: effect of statin therapy on disease progression. Am J Med 2004; 116:31-36.
17. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363:369-370.
18. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. J Am Med Assoc 2004; 292:331-337.
19. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116:664-668. A study that shows that early initiation of statin therapy in children with familial hypercholesterolemia might be beneficial in the prevention of atherosclerosis in adolescence.
20. Van Dam MJ, de Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002; 359:37-42.
21. Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44:1429-1435.
22. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment. A meta-analysis of randomized controlled trials. Stroke 2006; 37:1933-1940. A meta-analysis showing that antihypertensive treatment reduces carotid intima-media thickening.
23. Zheng L, Hodis HN, Buchanan TA, et al. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Am J Cardiol 2007; 99:956-960. A study showing that the antiatherogenic effect of antihypertensive agents can be detected by B-mode ultrasound in patients with diabetes mellitus.
24. Lange LA, Carlson CS, Hindorff LA, et al. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. J Am Med Assoc 2006; 296:2703-2711. An interesting study, showing that there is no association between carotid intima-media thickness and C-reactive protein gene polymorphisms.
25. Lee WY, Allison MA, Kim DJ, et al. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 2007; 99:99-102. A study showing that interleukin-6 and C-reactive protein are associated with carotid intima-media thickness, but the association of C-reactive protein was independent of interleukin-6.
26. Thakore AH, Guo CY, Larson MG, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007; 99:1598-1602. A large study showing a correlation between C-reactive protein and internal carotid intima-media thickness, but not with common carotid intima-media thickness or carotid stenosis.
27. Cao JJ, Arnold AM, Manolio TA, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116:32-38. A study showing that, in older adults, elevated C-reactive protein was associated with increased risk for CVD and all-cause mortality only in those with detectable atherosclerosis based on carotid ultrasound.
28. Touboul PJ, Vicaut E, Labreuche J, et al. Correlation between the Framingham risk score and intima media thickness: The Paroi Artérielle et Risque Cardiovasculaire (PARC) study. Atherosclerosis 2007; 192:363-369. A study showing that there is no clear correlation between CIMT and Framingham Risk Score.
29. Junyent M, Zambon D, Gilabert R. Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score. Atherosclerosis 2007 [Epub ahead of print]. A study showing that there is no clear correlation between CIMT and Framingham Risk Score.
30. Grewal J, Anand S, Islam S, et al. Prevalence and predictors of subclinical atherosclerosis among asymptomatic 'low risk' individuals in a multiethnic population. Atherosclerosis 2007 [Epub ahead of print]. A study showing that many individuals classified at low CHD risk by the Framingham Score have subclinical atherosclerosis.
31. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366:1267-1278.
32. Birjmohun RS, Hutten BA, Kastelein JP, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185-197.
33. Crouse JR 3rd, Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75:455-459.
34. Byington RB, Furberg CD, Crouse JR 3rd, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 76:54C-59C.
35. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial (MARS). Ann Intern Med 1996; 124:548-556.
36. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID atherosclerosis substudy. LIPID Trial Research Group. Circulation 1998; 97:1784-1790.
37. De Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31:1561-1567.
38. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-581.
39. Markwood TT, Kent SM, Coyle LC, et al. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) - a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness. Am Heart J 2001; 141:342-347.
40. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-2060.
41. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90:1679-1687.
42. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metroprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103:1721-1726.
43. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101:627-634.
44. Salonen R, Nyyssönen K, Porkkala E, et al. A population-based primary preventive trial of the effect of LDL lowering on atherosclerosis progression in carotid and femoral arteries. Circulation 1995; 92:1758-1764.
45. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the treatment effect of reducing cholesterol (ARBITER) 2. A double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
46. Taylor AJ, Lee HJ, Sullenberg LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22:2243-2250.
47. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of cholestipol-niacin therapy on common carotid artery. Two- and four-year reduction in intima-media thickness measured by ultrasound. Circulation 1993; 88:20-28.
48. Mack WJ, Selzer RH, Hodis HN, et al. One-year reduction and longitudinal analyses of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993; 24:1779-1783.
49. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. J Am Med Assoc 2007; 297:1344-1353. A randomized controlled trial showing that rosuvavastatin reduces the progression of atherosclerosis in subjects with low cardiovascular risk scores and asymptomatic atherosclerosis.
50. Kastelein JJP, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia (RADIANCE 1). N Engl J Med 2007; 356:1620-1630. A randomized controlled trial showing that CETP inhibition with torcetrapib significantly increases HDL-C levels and reduces LDL-C levels, but has no effect on the progression of atherosclerosis in subjects with familial hypercholesterolemia.
51. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomized controlled, double blind trial. Lancet 2007; 370:153-160. A randomized controlled trial showing that CETP inhibition with torcetrapib significantly increases HDL-C levels and reduces LDL-C levels, but has no effect on the progression of atherosclerosis in subjects with mixed dyslipidemia.
52. Cholesterol: the good, the bad, and the stopped trials. Lancet 2006; 368:2034.
53. Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128:262-269.
54. Espeland MA, O'Leary DH, James GT, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Contr Trials Cardiovasc Med 2005; 6:3.
55. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS/TEXCAPS). J Am Med Assoc 1998; 279:1615-1622.
56. Shepherd J, Cobb SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). N Engl J Med 1995; 333:1301-1307.
57. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Am Med Assoc 2002; 288:2998-3007.
58. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med 1996; 335:1001-1009.
59. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels (LIPID). N Engl J Med 1998; 339:1349-1357.
60. Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630.
61. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: A randomized controlled trial. J Am Med Assoc 2005; 294:2437-2445.
62. Deedwania P, Stone PH, Bairey CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Results of the Study Assessing Goals in Elderly (SAGE). Circulation 2007; 115:700-707.
63. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT). N Engl J Med 2004; 350:1495-1504.
64. Campeau L, Knatterud GL, Domanski M, et al. The effect of agressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphaenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162.
65. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 2000; 1:810-820.
66. Crowe LA, Gatehouse P, Yang GZ, et al. Volume-selective 3D turbo spin echo imaging for vascular wall imaging and distensibility measurement. J Magn Reson Imaging 2003; 17:572-580.
67. Varghese A, Crowe LA, Mohiaddin RH, et al. Interstudy reproducibility of three-dimensional volume-selective fast spin echomagnetic resonance for quantifying carotid artery wall volume. J Magn Reson Imaging 2005; 21:187-191.
68. Mohiaddin RH, Burman ED, Prasad SK, et al. Glagov remodeling of the atherosclerotic aorta demonstrated by cardiovascular magnetic resonance: the CORDA asymptomatic subject plaque assessment research (CASPAR) project. J Cardiovasc Magn Reson 2004; 6:517-525.
69. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104:249-252.
70. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106:2884-2887.
71. Lima JAC, Desai MY, Steen H, et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004; 110:2336-2341.
72. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005; 45:733-742.
73. Zhao X-Q, Yuan C, Hatsukami TS, et al. Effects of prolonged lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case-control study. Arterioscler Thromb Vasc Biol 2001; 21:1623-1629.
74. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus convetional lipid-lowering therapy by simvastatin on human atherosclerotic lesions. J Am Coll Cardiol 2005; 46:106-112.
75. Ayaori M, Momiyama Y, Fayad ZA, et al. Effects of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 2006 [Epub ahead of print].
76. Cai J, Hatsukami TS, Furguson MS, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005; 112:3437-3444.